ArticleAmerican journal of translational research2019
Long non-coding RNA MEG3 impacts diabetic nephropathy progression through sponging miR-145.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Correlation of differential expression of MEG3 lnc-RNA with biochemical parameters in Type-II diabetic patients with and without diabetic kidney disease.Pakistan journal of medical sciences · 2026Article
- Bushen Tongluo recipe improves oxidative stress homeostasis, inhibits transforming growth factor/Notch signaling pathway, and regulates the lncRNA maternally expressed gene 3/miR-145 axis to delay diabetic kidney disease.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Inhibition of LINC00707/miR-223-3p/FKBP5 axis has a protective effect on diabetic kidney disease.Journal of diabetes investigation · 2025Article
- Long noncoding RNA MEG3: an active player in fibrosis.Pharmacological reports : PR · 2025Review
- LncRNA GAS5 reduces blood glucose levels and alleviates renal fibrosis in diabetic nephropathy by regulating the miR-542-3p/ERBB4 axis.Diabetology & metabolic syndrome · 2025Article
- Understanding the Roles of Non-coding RNAs and Exosomal Non-Coding RNAs in Diabetic Nephropathy.Current molecular medicine · 2025Review
- The Association of Cell-Free LncH19 and miR-29b Expression with the PI3K/AKT/HIF-1/VEGF Pathway in Patients with Diabetic Nephropathy: In Silico Prediction and Clinical Validation.Current issues in molecular biology · 2024Article
- Long non-coding RNA MEG3 silencing weakens high glucose-induced mesangial cell injury by decreasing LIN28B expression by sponging and sequestering miR-23c.Kidney research and clinical practice · 2024Article
- LncRNA MEG3 inhibits renal fibrinoid necrosis of diabetic nephropathy via the MEG3/miR-21/ORAI1 axis.Molecular biology reports · 2023Article
- The long noncoding RNA Meg3 mediates TLR4-induced inflammation in experimental obstructive nephropathy.Clinical science (London, England : 1979) · 2023Article
- Exosomes from high glucose-treated macrophages promote epithelial-mesenchymal transition of renal tubular epithelial cells via long non-coding RNAs.BMC nephrology · 2023Article
- Circ_0060077 Knockdown Alleviates High-Glucose-Induced Cell Apoptosis, Oxidative Stress, Inflammation and Fibrosis in HK-2 Cells via miR-145-5p/VASN Pathway.Inflammation · 2022Article
- Long Noncoding RNA MEG3-205/Let-7a/MyD88 Axis Promotes Renal Inflammation and Fibrosis in Diabetic Nephropathy.Kidney diseases (Basel, Switzerland) · 2022Article
- Regulation of Oxidative Stress by Long Non-Coding RNAs in Vascular Complications of Diabetes.Life (Basel, Switzerland) · 2022Review
- lncRNA MEG3 modulates hepatic stellate cell activation by sponging miR‑145 to regulate PPARγ.Molecular medicine reports · 2022Article
- The role of lncRNAs in regulation of DKD and diabetes-related cancer.Frontiers in oncology · 2022Review
- SNHG15 knockdown inhibits diabetic nephropathy progression in pediatric patients by regulating the miR-141/ICAM-1 axis in vitro.Bioscience reports · 2021Article
- Review
- Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNA MEG3 has been reported to implicate in the progression of several cancers. Nevertheless, few studies have focused on the role of MEG3 in the development of diabetic nephropathy. Here, we demonstrated MEG3 was differently expressed by > 4 fold and was elevated significantly using lncRNA microarray in DN patient serum. Besides, MEG3 knockdown alleviated proliferation, fibrosis and induced apoptosis of mesangial cells under high glucose condition. Furthermore, bioinformatics predictions showed that MEG3 is a direct target of miR-145. In the vivo experiment, we found MEG3 silencing decreased the laboratory indicators and fibrosis-related protein secretion in db/db mice. Altogether, our study suggests MEG3 may play as an important role in progression of diabetic nephropathy, contributing to a novel understanding of pathogenesis and underlying therapeutic strategies for diabetic nephropathy.
Indexed as
Identifiers
31737219PMC6834487W2989663699What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.